biotechnology

Pitch Deck Teardown: Pepper Bio’s $6.5M seed deck

This week, we are taking a closer look at Pepper Bio's seed pitch deck that landed the company $6.5 million.

5 strategies for biotech startups to outlast a market downturn

To ensure survival, it’s essential to explore alternative funding methods rather than relying solely on classic fundraising.

5 investors explain why longevity tech is a long-term play

It’s becoming clear that longevity as a theme has resonated with investors, though it appears it will be some time before more generalist investors take interest.

Your future shrimp meal could come from Atarraya’s farming technology

The company's three-pronged technology includes creating ideal environment for the shrimp, remote operations management and AI-powered automation to monitor and feed them.

It’s the era of at-home health diagnostics and Senzo is finding its flow

Biotech company Senzo just raised a $2 million round at a $20 million pre-money valuation to further extend options for lateral flow diagnostics. “Lateral flow,” in this case, is the same

Hong Kong’s AI drug discovery firm Insilico closes $60M Series D

Insilico Medicine, a Hong Kong-based company that has been using artificial intelligence to discover new drugs since 2014, has completed a fresh round of funding. It’s a sign that certain invest

Planetary wants to help food startups brew up more fake meat

Planetary aims to bring all of the alternative protein production planets into orbit with its scaling technology.

How compassion and inclusivity are helping Kindbody change the fertility industry

When the topic of fertility comes up, we often hear hushed tones discussing someone else’s or their own journey through infertility.

6 questions investors should ask when evaluating psychedelic biotech companies

We believe in a future where psychedelic therapy will be as common as going to the dentist, but the path won’t be easy.

NovaXS Biotech wants to make injection therapy needle-free

A startup spawned from a lab at the University of California, Berkeley has won investor support to work on its patented needle-free injector, which it hopes can make therapies that traditionally requi

COVID rapid tests available on e-commerce in China for the first time

China is allowing the public to take COVID-19 rapid antigen self-tests for the first time as infection numbers hit a two-year high in recent days. Online marketplaces including JD.com and Meituan are

Startup Battlefield winner Cellino grabs $80M Series A

Cellino Bio’s founder Nabiha Saklayen didn’t initially intend to enter TechCrunch Disrupt 2021’s Startup Battlefield — it was her PR advisor who threw the startup’s name in the ring as a

MycoWorks, making leather from fungi, closes $125M to scale production

The company touts its Fine Mycelium process as the only mycelium engineered to be made-to-order and made-to-specification.

Phytoform plants $5.7M into climate-resistant crop technology

The success of CRISPR technology in agriculture has been well documented as a way to manipulate plant genomes to make them more pest and climate resistant and grow more consistent products.

Longevica takes in $2.5M as it launches open research resources to examine life extension

Longevica's goal is to validate the pipeline of turning scientific research into consumer-ready products.

Tiamat Sciences cooking up plant-based proteins for cheaper production of cellular meat

Adil estimates that today’s growth factor costs $2 million per gram to make, but she believes that with efforts from Tiamat Sciences and others, that cost could come down 10 times.

Generate Biomedicines raises $370M Series B with a focus on protein-based drugs

The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.  Generate Biomedicines

Kiwi Bio aims to free irritable bowel syndrome sufferers from restrictive diets

The company has been busy strengthening its supply chain to gear up for scaling its product. Additionally, it hired a head of growth and a community engagement and success manager.

Cellino is using AI and machine learning to scale production of stem cell therapies

Cellino, a company developing a platform to automate stem cell production, presented today at TechCrunch Disrupt 2021’s Startup Battlefield to detail how its system, which combines AI technology

The next healthcare revolution will have AI at its center

Human life expectancy increased from 31 years in 1900 to 72 years in 2017. Today, we are on the cusp of another healthcare revolution driven by artificial intelligence.
Load More